Parkinson's Disease

Arizona

26 Parkinson's Disease Trials near Arizona

Power is an online platform that helps thousands of Parkinson's Disease patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Tavapadon for Parkinson's Disease

Scottsdale, Arizona
This trial is testing a medication called tavapadon to see if it is safe and effective for people with Parkinson's Disease. The medication aims to help manage symptoms like tremors and stiffness by targeting specific parts of the brain.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40 - 80

992 Participants Needed

ND0612 for Parkinson's Disease

Phoenix, Arizona
This is a multi-center, randomized, double-blind, double-dummy, active controlled clinical Study. Following a screening period, eligible subjects will be enrolled to an open-label oral IR-LD/CD adjustment period; then an open-label ND0612 conversion period; then after optimization periods subjects will be randomized to receive either ND0612 or its matching Placebo with IR-LD/CD. Subjects can continue to an optional open-label extension period.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:30 - 80

381 Participants Needed

ABBV-951 Infusion for Parkinson's Disease

Scottsdale, Arizona
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated. ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants with advanced PD and who have completed M15-736 or M20-339 study will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 60 sites in the United States and Australia. Participants will receive continuous subcutaneous infusion (CSCI) (under the skin) of ABBV-951 for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical and remote telephone assessments, blood tests, checking for side effects, and completing questionnaires.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:30+

118 Participants Needed

ABBV-951 for Parkinson's Disease

Sun City, Arizona
This trial is testing a new drug called ABBV-951 for adults with advanced Parkinson's disease. The drug is given in a way to help control symptoms. Participants will be monitored through periodic check-ins to ensure the drug's safety and effectiveness.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:30+

130 Participants Needed

NEU-411 for Parkinson's Disease

Sun City, Arizona
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 50-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway. Participants will: • Take NEU-411 or placebo every day for 52 weeks

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 80

150 Participants Needed

IkT-148009 for Parkinson's Disease

Scottsdale, Arizona
This trial tests the safety and effects of IkT-148009, a daily pill, in people aged 30 to 80 with untreated Parkinson's disease. The drug aims to block an enzyme that may help manage symptoms. Participants will take the drug for a few months.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:30 - 80

120 Participants Needed

BIIB122 for Early-Stage Parkinson's Disease

Sun City, Arizona
This trial is testing a new drug called BIIB122 to see if it can slow down symptoms in people with early-stage Parkinson's disease. The drug works by blocking a protein that may cause the disease to get worse. Participants will take the drug for several years to see if it helps.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:30 - 80

650 Participants Needed

BIA 28-6156 for Parkinson's Disease

Phoenix, Arizona
This trial is testing a new drug called BIA 28-6156 to see if it can slow down movement problems in people with Parkinson's disease who have a specific genetic mutation. The study will compare the drug to another treatment over a period of several months.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:35 - 80

237 Participants Needed

Lenrispodun for Parkinson's Disease

Scottsdale, Arizona
This trial is testing a medication called Lenrispodun to help people with Parkinson's Disease. It aims to reduce symptoms that appear when their usual medication stops working and to control involuntary movements caused by their current treatment. The study involves an initial check-up, a phase where patients receive either Lenrispodun or another substance, and a later check-up to ensure safety.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:40 - 80

132 Participants Needed

Prasinezumab for Early Parkinson's Disease

Phoenix, Arizona
This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous prasinezumab (RO7046015/PRX002) versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of three parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2). Participants who complete Part 2 (including the 12-week treatment-free follow up visit assessing long term safety and efficacy of RO7046015) will be offered participation in Part 3 open-label extension (all-participants-on-RO7046015-treatment) for an additional 260 weeks.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40 - 80

316 Participants Needed

Continuous Subcutaneous Infusion of Levodopa/Carbidopa for Parkinson's Disease

Phoenix, Arizona
This trial tests a pump that delivers medication under the skin for patients with advanced Parkinson's Disease. The treatment aims to improve movement symptoms by increasing dopamine levels in the brain. This method has been used for many years to manage motor complications in advanced Parkinson's Disease.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:30+

214 Participants Needed

Allopregnanolone for Parkinson's Disease

Tucson, Arizona
The goal of this open-label, pilot clinical trial is to test allopregnanolone as a regenerative treatment in patients with Parkinson's disease (PD). The main questions this study aims to answer are: 1. Is a large-scale clinical trial testing how well it works in patients with PD feasible? 2. Is allopregnanolone safe and well-tolerated in patients with PD. 3. Can we see any signals of changes in imaging and clinical scales? Participants will receive a weekly infusion in their vein of allopregnanolone for a total of 12 weeks. There is no placebo so everyone receives allopregnanolone and "Open-label" means the study is not blinded so both the participant and investigators know the assigned treatment.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:40 - 85

10 Participants Needed

ANPD001 for Parkinson's Disease

Tucson, Arizona
This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 1
Age:50 - 70

9 Participants Needed

CereGate Therapy for Freezing of Gait in PD

Phoenix, Arizona
A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 80

41 Participants Needed

Genetic Registry for Parkinson's Disease

Phoenix, Arizona
Development of a central repository for PD-related genomic data for future research.
No Placebo Group

Trial Details

Trial Status:Recruiting

25000 Participants Needed

Rehabilitation Approaches for Freezing of Gait in Parkinson's Disease

Tempe, Arizona
The goals of this clinical trial are to 1) learn how two different rehabilitation interventions for PD can reduce Freezing of Gait (FOG) in people with Parkinson's disease, as assessed by patients, clinicians, and wearable sensors, and 2) to explore whether two different rehabilitation intervention can reduce FOG and improve daily life mobility in people with FOG sufficiently to justify a clinical trial. Participants will: * Be randomly assigned to one of two intervention groups (turning-focused agility exercise or strength-based exercise) * Have one-on-one training sessions three times per week for 6 weeks * Perform in-lab assessments before beginning and after completing the study intervention * Use wearable mobility sensors during daily life to measure their walking and balance
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:50 - 80

60 Participants Needed

DBS Surgery for Parkinson's Disease

Phoenix, Arizona
This is a mechanistic study to determine the differential effects of the dopaminergic and cholinergic systems on attention, gait, and balance. The primary goal of the study is to evaluate the relative effects of pedunculopontine nucleus (PPN) and subthalamic nucleus (STN) Deep Brain Stimulation (DBS) on these features in persons with Parkinson's Disease (PD) who are eligible for DBS for improvement of their motor symptoms and exhibit gait instability with falls. Patients will be enrolled and implanted with bilateral electrodes in one of the approved DBS locations (subthalamic nucleus: STN), but additionally electrodes will be inserted into the experimental target, namely the PPN bilaterally.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased

8 Participants Needed

UCB0022 for Parkinson's Disease

Phoenix, Arizona
This trial is testing UCB0022, a new medication, to see if it can help people with advanced Parkinson's Disease. It is added to their regular treatments to see if it reduces the time they spend with bad symptoms. The goal is to make their usual treatments work better.
Stay on current meds

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:35 - 85

207 Participants Needed

Minzasolmin for Parkinson's Disease

Phoenix, Arizona
The purpose of the study is to estimate the pharmacodynamic effects of minzasolmin (UCB0599) on brain pathophysiology in Early-start versus Delayed-start participants originally diagnosed with new onset Parkinson's disease.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:40 - 78

428 Participants Needed

Genetic Testing for Parkinson's Disease

Phoenix, Arizona
To assess the feasibility, impact, and participant satisfaction of offering Clinical Laboratory Improvement Amendments (CLIA) certified genetic testing as part of clinical care for People with Parkinson's disease (PWP).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

1982 Participants Needed

Why Other Patients Applied

"It seems my Parkinson’s is progressing more rapidly now. And my meds are lagging behind. My off time is more frequent and the episodes are longer. Trying to figure out what my options are."

TM
Parkinson's PatientAge: 58

"I wasn’t diagnosed until February, but I showed symptoms over ten years before. I want to help find a cure. I have lost family members to Parkinson’s and want to contribute to the search for better treatments before my children possibly come down with it."

YX
Parkinson's PatientAge: 61

"I have 5 kids. I'll do anything I can to slow this disease down in hopes that I can stay active with them into their adulthood. I also feel I am serving the greater good for all those who suffer from Parkinson's. Since I'm self employed, my schedule is flexible. "

UR
Parkinson's PatientAge: 53

"My dad was in a research group for Parkinson's for about 6 years, which was very interesting. I was just diagnosed 1.5 years ago, and started on low dose Sinemet. Doing well on Sinemet, but I'd like to get ahead of the condition. I'm excited about participating in research. "

LN
Parkinson's PatientAge: 74

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

CVN424 Monotherapy for Early Parkinson's Disease

Scottsdale, Arizona
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.

Trial Details

Trial Status:Active Not Recruiting
Age:30+

62 Participants Needed

Long-Term Treatment for Parkinson's Disease

Scottsdale, Arizona
This study seeks to establish the safety and efficacy of extended twice daily treatments for treating symptoms associated with PD. Only participants who completed the STEM-PD RCT trial are eligible for the OLE.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation

220 Participants Needed

Zoledronic Acid for Parkinson's Disease

Scottsdale, Arizona
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 2650 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:60+

2650 Participants Needed

Suvecaltamide for Tremors in Parkinson's Disease

Scottsdale, Arizona
This trial tests suvecaltamide, a medication aimed at reducing severe tremors in adults with Parkinson's disease whose current treatments are not effective. The medication likely helps by calming the overactive nerves or muscles responsible for the tremors.

Trial Details

Trial Status:Recruiting
Age:40 - 85

160 Participants Needed

Gene Transfer for Pompe Disease

Phoenix, Arizona
This trial is testing a new treatment called SPK-3006 for adults with late-onset Pompe disease who are already on enzyme replacement therapy. The treatment involves an infusion that delivers a gene to help produce a missing enzyme. The goal is to see if this new approach is safe and effective.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

4 Participants Needed

AMX0035 for Progressive Supranuclear Palsy

Scottsdale, Arizona
A35-009 (ORION) is a Phase 2b/3 trial to evaluate the efficacy and safety of AMX0035 in participants with Progressive Supranuclear Palsy (PSP), consisting of randomized, double blind placebo controlled phases, followed by an optional open-label extension phase.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:40 - 80

110 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Parkinson's Disease clinical trials in Arizona pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Parkinson's Disease clinical trials in Arizona work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Parkinson's Disease trials in Arizona 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Arizona for Parkinson's Disease is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Arizona several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Parkinson's Disease medical study in Arizona?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Parkinson's Disease clinical trials in Arizona?

Most recently, we added Rehabilitation Approaches for Freezing of Gait in Parkinson's Disease, NEU-411 for Parkinson's Disease and ANPD001 for Parkinson's Disease to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Clinical Trials near Arlington Heights, IL

174 Clinical Trials near Brownsville, TX

Top Clinical Trials near Artesia, CA

Top Adenocarcinoma Clinical Trials

Top Clinical Trials near Goldsboro, NC

Top Uti Clinical Trials

Top Head And Neck Squamous Cell Carcinoma Clinical Trials

Top Clinical Trials near Clarksville, TN

Top Esophagus Cancer Clinical Trials

Top Hydrocephalus Clinical Trials

207 Clinical Trials near Azusa, CA

22 Bipolar Disorder Trials near Fort Worth, TX

By Trial

Transcatheter Tricuspid Valve Replacement for Tricuspid Regurgitation

Technology-based Body and Mind Intervention for Fall Prevention in Older Adults

KP001 for Safety Evaluation

Furosemide for High Blood Pressure

Tdap Vaccine Safety Study for Plasma Donors

Oral THC and CBD for Substance Use Disorders

Recruitment Strategies for Family Members in the ICU

Pre-Exercise Protein for Perimenopause

CH505 TF chTrimer Vaccine for HIV Prevention

FOLFIRINOX + 9-ING-41 for Pancreatic Cancer

Biomarker Testing for Head Trauma

Durvalumab + Tremelimumab ± Chemotherapy for Lung Cancer

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial